282 related articles for article (PubMed ID: 8736323)
1. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
Nagaoka T; Sato S; Hasegawa M; Ihn H; Takehara K
J Rheumatol; 2000 Aug; 27(8):1917-21. PubMed ID: 10955333
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
[TBL] [Abstract][Full Text] [Related]
4. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
Steen VD; Engel EE; Charley MR; Medsger TA
J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
6. [Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation].
Lis AD; Brzezińska-Wcisło LA
Wiad Lek; 2003; 56(11-12):532-6. PubMed ID: 15058159
[TBL] [Abstract][Full Text] [Related]
7. The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8.
Dooley MA; Cush JJ; Lipsky PE; Dawson DV; Pisetsky DS
J Rheumatol; 1993 Nov; 20(11):1857-62. PubMed ID: 8308770
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
9. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
[TBL] [Abstract][Full Text] [Related]
10. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma.
Patrick MR; Kirkham BW; Graham M; Harrision LC
J Rheumatol; 1995 Apr; 22(4):654-8. PubMed ID: 7791158
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity.
Yosipovitch G; Shohat B; Bshara J; Wysenbeek A; Weinberger A
Isr J Med Sci; 1995 Jun; 31(6):345-8. PubMed ID: 7607852
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
14. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
[TBL] [Abstract][Full Text] [Related]
15. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of increased serum soluble interleukin-2 receptor levels in patients with pulmonary tuberculosis].
Chui JJ; Fan P; Li J
Zhonghua Jie He He Hu Xi Za Zhi; 1994 Oct; 17(5):288-90, 318-9. PubMed ID: 7712570
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of manganese superoxide dismutase in patients with localized scleroderma.
Jinnin M; Ihn H; Yazawa N; Asano Y; Yamane K; Tamaki K
Exp Dermatol; 2004 Jun; 13(6):357-60. PubMed ID: 15186321
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclosporine A on serum and urinary soluble interleukin-2 receptor in patients with lupus nephritis.
Tang Z; Zhang J; Zhang S; Li L
Chin Med J (Engl); 1997 Sep; 110(9):686-9. PubMed ID: 9642325
[TBL] [Abstract][Full Text] [Related]
19. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage.
Schmitt WH; Csernok E; Kobayashi S; Klinkenborg A; Reinhold-Keller E; Gross WL
Arthritis Rheum; 1998 Mar; 41(3):445-52. PubMed ID: 9506572
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor in pancreatic cancer and chronic pancreatitis.
Pezzilli R; Billi P; Beltrandi E; Mancini R; Casadei-Maldini M; Casadei R; Greco VM; Campione O; Miglioli M
Ital J Gastroenterol; 1994 Apr; 26(3):137-40. PubMed ID: 8061340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
